Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448420 | 0.80 | GRM2 (0.50) | GRM2HSD11B1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL8941864 | 0.77 | HSD11B1 (0.43) | GRM2HSD11B1GFERMGLLRAB9A | |
| SCHEMBL4455582 | 0.74 | TNKS (0.39) | GRM2 | |
| SCHEMBL4467712 | 0.72 | GRM2 (0.45) | GRM2RAB9ASMN1; SMN2EGFRKDM4E | |
| SCHEMBL8941897 | 0.70 | GRM2 (0.42) | GRM2HSD11B1KDM4EMEN1GAA | |
| SCHEMBL8941935 | 0.69 | ALDH1A1 (0.44) | GRM2HSD11B1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL21944956 | 0.68 | SMN1; SMN2 (0.60) | HSD11B1GFERMGLLRAB9APOLB | |
| SCHEMBL20408735 | 0.67 | L3MBTL1 (0.52) | HSD11B1GFERPOLBMEN1MAPT | |
| SCHEMBL22422907 | 0.66 | GRM2 (0.58) | GRM2POLB | |
| SCHEMBL14382111 | 0.66 | HSD11B1 (0.54) | HSD11B1MGLLRAB9APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | GRM2 4432/4885HSD11B1 945/4885APP 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.